Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Summary

The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral eleclazine and its metabolite, GS-623134, in participants with normal and impaired hepatic function. Participants in the healthy control group will be matched to participants with impaired hepatic function by age (± 5 years), gender, and body mass index (± 10%).

Timeline

Start

2015-03-19

Primary completion

2016-04-22

Completion

2016-04-22

Drugs

Indications